Drugs / BT01001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07313722 | Nov 2025 → Feb 2026 overdue | — | Beyang Therapeutics Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BT01001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07313722 ↗ |
| Route | Topical | “BT01001 Ophthalmic Solution will be administered as topical instillation into the right eye of each subject according to the assigned dosing schedule.” NCT07313722 ↗ |